clinical trial · NCT06989359
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
ADARx Pharmaceuticals, Inc.·phase2·recruiting·n = 45
IgANC3GComplement-mediated Kidney DiseaseIgA Nephropathy (IgAN)IC-MPGNADX-038 Dose Level 2ADX-038 Dose Level 1
brief summary
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
started
Aug 28, 2025
primary completion
Dec 31, 2028
completion
Jun 1, 2029
last updated
Jun 8, 2026
official title
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol